Fortune India 500 2025 edition
Rank#100- Total income
- ₹28,742 Cr
- Profit
- ₹5,273 Cr
Last year #92
Cipla Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Active Listed - NSE: CIPLA · BSE: 500087 Public Limited Company pharma Fortune India 500 · #100 India's Most Valuable Nifty 50
Market Cap
₹1,07,520 Cr
CIPLA · NSE
Share Price
₹1,338.00
+0.53% today
Revenue
₹39,012 Cr
FY 2025-26 · +5.3% YoY
EBITDA
₹5,607 Cr
Margin 14.4%
Net Profit
₹3,806 Cr
FY 2025-26 · -26.0% YoY
P/E (TTM)
29.7x
P/B 3.1x
ROE
11.8%
ROCE 15.7%
Debt / Equity
0.02
Interest cover 1.2x
About Cipla Limited
Data last updated:
Cipla Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 17 August 1935 and has been in existence for over 91 years.
Cipla is ranked #100 on the Fortune India 500 (2025). It is part of the Nifty 50, Nifty 500 and BSE 500 indices. Its director Yusuf Hamied and family are #155 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1935PLC002380. Its GSTIN is 27AAACC1450B1ZE (Maharashtra). The company holds 38 GST registrations, of which 30 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500087 and NSE: CIPLA.
The company has an authorised share capital of ₹175 Cr and a paid-up capital of ₹161.57 Cr. It was formerly known as The Chemical Industrial and Pharmaceutical Laboratories Limited. It is led by directors including Achin Gupta (Managing Director) and Prathivadibhayankara Rajagopalan Ramesh.
Its last annual general meeting (AGM) was held on 16 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Cipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹39,012 Cr, a growth of 5.3% compared to the previous year. For the same year it recorded a net profit of ₹3,806.3 Cr (net margin 9.8%) and EBITDA of ₹5,606.99 Cr (EBITDA margin 14.4%). The net worth stands at ₹34,432 Cr (up 10.4% YoY). Total assets are valued at ₹35,561 Cr (up 11% YoY).
The company has about 25,952 employees on its provident fund (EPFO) records. Its group structure includes 9 subsidiaries.
The company is associated with 3 brands: Ciplamed, Mirren and Cipla. As per MCA filings, the company has satisfied charges of ₹68.5 Cr on record. Court records list 996 cases involving the company, including 501 filed by the company and 495 filed against it; 182 cases are pending. The company has 45 deals on record (41 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹675.99 Cr; the latest was in October 2025. Its 8 peer companies in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cipla.com.
Company details
CIN L24239MH1935PLC002380
Registration Number 002380
Incorporation Date 17 August 1935
ROC Mumbai
Listing Status Listed - Listed on NSE (CIPLA); Listed on BSE (500087)
Company Status Active
Date of Last AGM 16 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Achin Gupta Managing Director Prathivadibhayankara Rajagopalan Ramesh Director Mandar Purushottam Vaidya Director Recognitions & Rankings of Cipla
India's Most Valuable Companies 2025 edition · Source: Hurun India
2024 #47 2023 #39 2022 #43
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #155 Yusuf Hamied & family ₹23,700 Cr
Stock market indices
Nifty 50 Nifty 500 BSE 500
Contact details
Cipla Limited's registered office is in Mumbai, Maharashtra. Its website is cipla.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressCipla House Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
- IndustryPharma, API Manufacturers, Drug Formulation & Development
To see the full contact details of Cipla Limited, buy the company report.
Comprehensive company report
Cipla Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Cipla operates multiple associated brands including Ciplamed, Mirren, and Cipla. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers online medical news, guidelines, and educational content for professionals. | ciplamed.com | |
| Natural gas assets are developed alongside innovative pipeline solutions. | mirren.co.za | |
| APIs, generic drugs, and formulation services are manufactured. | cipla.com |
Business activity
The main business activities of Cipla are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Cipla Limited, buy the company report.
Financials of Cipla Limited
FY 2025-26 filings availableCipla Limited reported revenue of ₹39,012 Cr (up 5.3% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹39,012 Cr
+5.3% YoY
EBITDA
₹5,607 Cr
-21.3% YoY
Profit After Tax
₹3,806 Cr
-26.0% YoY
Net Worth
₹34,432 Cr
+10.4% YoY
Total Assets
₹35,561 Cr
+11.0% YoY
Total Debt
₹614 Cr
+40.1% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 39,012 | 37,039 | 35,415 | 30,938 | 29,719 | 28,227 | 17,132 |
| Revenue growth | +5.3% | +4.6% | +14.5% | +4.1% | +5.3% | +64.8% | - |
| EBITDA | 5,607 | 7,128 | 6,096 | 4,845 | 4,371 | 4,252 | 3,206 |
| EBITDA margin | +14.4% | +19.2% | +17.2% | +15.7% | +14.7% | +15.1% | +18.7% |
| Profit before tax | 5,224 | 6,821 | 5,702 | 4,038 | 3,493 | 3,290 | 2,178 |
| Net profit | 3,806 | 5,146 | 4,207 | 2,842 | 2,582 | 2,369 | 1,458 |
| Net profit margin | +9.8% | +13.9% | +11.9% | +9.2% | +8.7% | +8.4% | +8.5% |
| EPS (₹) | 48.02 | 65.29 | 51.05 | 34.71 | 31.19 | 29.82 | 19.18 |
| Balance sheet | |||||||
| Total assets | 35,561 | 32,035 | 27,621 | 24,785 | 22,425 | 20,878 | 19,351 |
| Net worth | 34,432 | 31,193 | 26,706 | 23,408 | 20,842 | 18,327 | 15,763 |
| Total debt | 614 | 438 | 559 | 803 | 1,056 | 2,014 | 2,816 |
| Cash & bank | 1,307 | 800 | 875 | 1,565 | 1,928 | 1,401 | 1,004 |
| Net working capital | 9,685 | 10,658 | 9,674 | 9,200 | 8,084 | 6,946 | 6,744 |
| Cash flow | |||||||
| Cash from operations | 3,940 | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 |
| Cash from investing | (2,234) | (3,682) | (2,982) | (2,376) | (1,858) | (2,374) | 114 |
| Cash from financing | (1,234) | (1,293) | (1,200) | (958) | (1,600) | (1,240) | (2,949) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,119 | 6,541 | 7,074 | 7,589 | 6,957 | 6,730 | 7,073 | 7,051 |
| Revenue growth (YoY) | +2.3% | -2.8% | +0.0% | +7.6% | +3.9% | - | - | - |
| Other income | 211 | 148 | 206 | 269 | 259 | 289 | 222 | 191 |
| EBITDA | 1,192 | 955 | 979 | 1,895 | 1,778 | 1,538 | 1,989 | 1,886 |
| EBITDA margin | +16.8% | +14.8% | +14.1% | +25.4% | +26.0% | +23.3% | +28.6% | +27.1% |
| Depreciation | 304 | 383 | 278 | 297 | 253 | 309 | 280 | 272 |
| Interest | 17.03 | 13.13 | 14.03 | 13.18 | 14.05 | 14.02 | 14.64 | 15.40 |
| Profit before tax | 1,082 | 707 | 893 | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 |
| Tax | 295 | 157 | 219 | 500 | 478 | 279 | 332 | 483 |
| Net profit | 787 | 550 | 675 | 1,353 | 1,292 | 1,225 | 1,584 | 1,306 |
| EPS (₹) | 9.76 | 6.86 | 8.36 | 16.72 | 16.06 | 15.12 | 19.43 | 16.12 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 20,065 | 19,952 | 17,483 | 15,058 | 15,381 | 11,303 | 12,659 |
| Revenue growth | +0.6% | +14.1% | +16.1% | -2.1% | +36.1% | -10.7% | - |
| EBITDA | 4,191 | 5,778 | 4,484 | 3,167 | 3,711 | 3,067 | 2,707 |
| EBITDA margin | +20.9% | +29.0% | +25.7% | +21.0% | +24.1% | +27.1% | +21.4% |
| Profit before tax | 4,636 | 6,469 | 5,310 | 3,375 | 3,880 | 3,208 | 2,964 |
| Net profit | 3,442 | 4,813 | 4,038 | 2,555 | 2,909 | 2,429 | 2,227 |
| Net profit margin | +17.2% | +24.1% | +23.1% | +17.0% | +18.9% | +21.5% | +17.6% |
| EPS (₹) | 43.52 | 63.86 | 50.50 | 31.14 | 36.66 | 30.61 | 28.75 |
| Balance sheet | |||||||
| Total assets | 34,667 | 32,414 | 28,174 | 24,875 | 22,718 | 20,190 | 17,679 |
| Net worth | 34,201 | 32,099 | 27,974 | 24,638 | 22,514 | 19,928 | 17,403 |
| Total debt | 125 | 117 | 45.55 | 50.09 | 23.45 | 52.12 | 6.06 |
| Cash & bank | 519 | 278 | 333 | 966 | 1,428 | 875 | 523 |
| Net working capital | 7,318 | 8,368 | 7,628 | 7,915 | 6,645 | 5,518 | 5,579 |
| Cash flow | |||||||
| Cash from operations | 2,832 | 3,301 | 3,727 | 3,035 | 2,773 | 3,460 | 2,018 |
| Cash from investing | (1,344) | (2,309) | (2,883) | (2,758) | (2,464) | (3,361) | (1,127) |
| Cash from financing | (1,322) | (1,074) | (709) | (425) | (427) | (65.80) | (694) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,078 | 4,210 | 4,498 | 5,226 | 5,046 | 4,798 | 4,971 | 4,775 |
| Revenue growth (YoY) | +0.6% | -12.3% | -9.5% | +9.4% | +12.1% | - | - | - |
| Other income | 243 | 180 | 417 | 255 | 271 | 588 | 189 | 289 |
| Total expenses | 3,992 | 3,643 | 4,021 | 3,703 | 3,422 | 3,479 | 3,309 | 3,337 |
| EBITDA | 1,086 | 567 | 477 | 1,523 | 1,624 | 1,319 | 1,662 | 1,438 |
| EBITDA margin | +23.2% | +14.8% | +11.2% | +33.9% | +36.1% | +31.0% | +40.2% | +36.2% |
| Depreciation | 169 | 218 | 153 | 141 | 146 | 148 | 143 | 146 |
| Interest | 5.68 | 6.74 | 4.03 | 2.65 | 5.88 | 3.49 | 3.55 | 3.00 |
| Profit before tax | 1,154 | 522 | 736 | 1,633 | 1,744 | 1,756 | 1,704 | 1,578 |
| Tax | 291 | 138 | 119 | 423 | 441 | 270 | 266 | 400 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,119 | 6,541 | 7,074 | 7,589 | 6,957 | 6,730 | 7,073 | 7,051 |
| Revenue growth (YoY) | +2.3% | -2.8% | +0.0% | +7.6% | +3.9% | - | - | - |
| Other income | 211 | 148 | 206 | 269 | 259 | 289 | 222 | 191 |
| EBITDA | 1,192 | 955 | 979 | 1,895 | 1,778 | 1,538 | 1,989 | 1,886 |
| EBITDA margin | +16.8% | +14.8% | +14.1% | +25.4% | +26.0% | +23.3% | +28.6% | +27.1% |
| Depreciation | 304 | 383 | 278 | 297 | 253 | 309 | 280 | 272 |
| Interest | 17.03 | 13.13 | 14.03 | 13.18 | 14.05 | 14.02 | 14.64 | 15.40 |
| Profit before tax | 1,082 | 707 | 893 | 1,854 | 1,770 | 1,504 | 1,916 | 1,789 |
| Tax | 295 | 157 | 219 | 500 | 478 | 279 | 332 | 483 |
| Net profit | 787 | 550 | 675 | 1,353 | 1,292 | 1,225 | 1,584 | 1,306 |
| EPS (₹) | 9.76 | 6.86 | 8.36 | 16.72 | 16.06 | 15.12 | 19.43 | 16.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 39,012 | 37,039 | 35,415 | 30,938 | 29,719 | 28,227 | 17,132 |
| Revenue growth | +5.3% | +4.6% | +14.5% | +4.1% | +5.3% | +64.8% | - |
| Other income | 882 | 862 | 747 | 475 | 281 | 266 | 344 |
| Total expenses | 33,405 | 29,911 | 29,319 | 26,093 | 25,349 | 23,975 | 13,926 |
| Employee cost | 5,366 | 4,833 | 4,310 | 3,830 | 3,530 | 3,252 | 3,027 |
| EBITDA | 5,607 | 7,128 | 6,096 | 4,845 | 4,371 | 4,252 | 3,206 |
| EBITDA margin | +14.4% | +19.2% | +17.2% | +15.7% | +14.7% | +15.1% | +18.7% |
| Depreciation | 1,211 | 1,107 | 1,051 | 1,172 | 1,052 | 1,068 | 1,175 |
| Interest | 54.39 | 62.01 | 89.88 | 110 | 106 | 161 | 197 |
| Profit before tax | 5,224 | 6,821 | 5,702 | 4,038 | 3,493 | 3,290 | 2,178 |
| Tax | 1,354 | 1,530 | 1,547 | 1,203 | 934 | 889 | 631 |
| Net profit | 3,806 | 5,146 | 4,207 | 2,842 | 2,582 | 2,369 | 1,458 |
| Net profit margin | +9.8% | +13.9% | +11.9% | +9.2% | +8.7% | +8.4% | +8.5% |
| EPS (₹) | 48.02 | 65.29 | 51.05 | 34.71 | 31.19 | 29.82 | 19.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 162 | 162 | 161 | 161 | 161 | 161 | 161 |
| Reserves & surplus | 34,270 | 31,032 | 26,545 | 23,246 | 20,680 | 18,165 | 15,602 |
| Shareholders' funds (net worth) | 34,432 | 31,193 | 26,706 | 23,408 | 20,842 | 18,327 | 15,763 |
| Minority interest | 88.29 | 95.80 | 95.90 | 306 | 276 | 259 | 294 |
| Secured loans | 0.00 | 11.98 | 91.77 | 429 | 376 | 392 | 423 |
| Unsecured loans | 614 | 426 | 468 | 374 | 680 | 1,622 | 2,393 |
| Total debt | 614 | 438 | 559 | 803 | 1,056 | 2,014 | 2,816 |
| Total liabilities | 35,561 | 32,035 | 27,621 | 24,785 | 22,425 | 20,878 | 19,351 |
| Assets | |||||||
| Gross block | 23,422 | 19,553 | 18,146 | 17,122 | 16,968 | 15,787 | 15,151 |
| Net block | 12,434 | 10,006 | 9,607 | 9,160 | 9,683 | 9,516 | 9,683 |
| Capital work in progress | 2,042 | 1,566 | 1,153 | 1,093 | 766 | 969 | 825 |
| Investments | 8,223 | 7,933 | 5,449 | 3,662 | 2,551 | 2,710 | 1,471 |
| Inventories | 6,597 | 5,642 | 5,238 | 5,156 | 5,350 | 4,669 | 4,378 |
| Sundry debtors | 5,620 | 5,506 | 4,771 | 4,057 | 3,424 | 3,446 | 3,891 |
| Cash & bank balances | 1,307 | 800 | 875 | 1,565 | 1,928 | 1,401 | 1,004 |
| Loans & advances | 2,942 | 4,007 | 3,702 | 2,937 | 1,813 | 1,407 | 1,417 |
| Total current assets | 16,466 | 15,956 | 14,585 | 13,715 | 12,516 | 10,923 | 10,690 |
| Total current liabilities | 6,782 | 5,298 | 4,912 | 4,515 | 4,432 | 3,977 | 3,946 |
| Net working capital | 9,685 | 10,658 | 9,674 | 9,200 | 8,084 | 6,946 | 6,744 |
| Total assets | 35,561 | 32,035 | 27,621 | 24,785 | 22,425 | 20,878 | 19,351 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 543 | 512 | 561 | 658 | 790 | 649 | 508 |
| Net cash from operating activities | 3,940 | 5,005 | 4,134 | 3,238 | 3,326 | 3,755 | 3,068 |
| Net cash from investing activities | (2,234) | (3,682) | (2,982) | (2,376) | (1,858) | (2,374) | 114 |
| Net cash from financing activities | (1,234) | (1,293) | (1,200) | (958) | (1,600) | (1,240) | (2,949) |
| Net change in cash | 473 | 30.31 | (48.99) | (96.78) | (132) | 141 | 234 |
| Closing cash | 1,307 | 800 | 875 | 1,565 | 1,928 | 1,401 | 1,004 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.3% | +4.6% | +14.5% | +4.1% | +5.3% | +64.8% | - |
| EBITDA growth | -21.3% | +16.9% | +25.8% | +10.8% | +2.8% | +32.6% | - |
| PBT growth | -23.4% | +19.6% | +41.2% | +15.6% | +6.2% | +51.1% | +4.8% |
| Net income growth | -26.0% | +22.3% | +48.0% | +10.1% | +9.0% | +62.5% | - |
| Revenue CAGR (3Y) | +8.0% | +7.6% | +7.9% | +21.8% | +22.0% | +23.0% | +6.0% |
| EBITDA CAGR (3Y) | +5.0% | +17.7% | +12.8% | +14.8% | +12.2% | +15.7% | +9.0% |
| Profitability & leverage | |||||||
| Net income margin | +9.9% | +14.3% | +11.7% | +9.2% | +8.6% | +8.5% | +9.0% |
| Return on capital employed | +15.7% | +23.2% | +22.3% | +17.8% | +16.8% | +17.4% | +12.2% |
| Return on net worth | +11.8% | +18.3% | +16.6% | +12.8% | +13.1% | +14.1% | +10.1% |
| Debt / equity | 0.02 | 0.02 | 0.03 | 0.04 | 0.08 | 0.14 | 0.23 |
| Long-term debt / equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.05 | 0.11 | 0.20 |
| Interest cover | 1.24 | 1.03 | 1.78 | 2.98 | 3.20 | 5.05 | 9.72 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.82 | 1.96 | 2.01 | 1.82 | 1.81 | 1.82 | 1.18 |
| Inventory turnover | 6.38 | 6.81 | 6.81 | 5.89 | 5.93 | 6.24 | 4.11 |
| Debtors turnover | 7.01 | 7.21 | 8.02 | 8.27 | 8.65 | 7.69 | 4.26 |
| EPS (₹) | 48.02 | 65.29 | 51.05 | 34.71 | 31.19 | 29.82 | 19.18 |
| Dividend per share (₹) | 13.00 | 16.00 | 13.00 | 8.50 | 5.00 | 5.00 | 4.00 |
| Book value per share (₹) | 426.24 | 386.25 | 330.79 | 290.01 | 258.33 | 227.25 | 195.51 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5,078 | 4,210 | 4,498 | 5,226 | 5,046 | 4,798 | 4,971 | 4,775 |
| Revenue growth (YoY) | +0.6% | -12.3% | -9.5% | +9.4% | +12.1% | - | - | - |
| Other income | 243 | 180 | 417 | 255 | 271 | 588 | 189 | 289 |
| Total expenses | 3,992 | 3,643 | 4,021 | 3,703 | 3,422 | 3,479 | 3,309 | 3,337 |
| EBITDA | 1,086 | 567 | 477 | 1,523 | 1,624 | 1,319 | 1,662 | 1,438 |
| EBITDA margin | +23.2% | +14.8% | +11.2% | +33.9% | +36.1% | +31.0% | +40.2% | +36.2% |
| Depreciation | 169 | 218 | 153 | 141 | 146 | 148 | 143 | 146 |
| Interest | 5.68 | 6.74 | 4.03 | 2.65 | 5.88 | 3.49 | 3.55 | 3.00 |
| Profit before tax | 1,154 | 522 | 736 | 1,633 | 1,744 | 1,756 | 1,704 | 1,578 |
| Tax | 291 | 138 | 119 | 423 | 441 | 270 | 266 | 400 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 20,065 | 19,952 | 17,483 | 15,058 | 15,381 | 11,303 | 12,659 |
| Revenue growth | +0.6% | +14.1% | +16.1% | -2.1% | +36.1% | -10.7% | - |
| Other income | 1,123 | 1,279 | 1,434 | 826 | 742 | 654 | 893 |
| Total expenses | 15,874 | 14,174 | 12,999 | 11,891 | 11,670 | 8,235 | 9,952 |
| Employee cost | 3,350 | 3,055 | 2,689 | 2,381 | 2,122 | 1,704 | 1,911 |
| EBITDA | 4,191 | 5,778 | 4,484 | 3,167 | 3,711 | 3,067 | 2,707 |
| EBITDA margin | +20.9% | +29.0% | +25.7% | +21.0% | +24.1% | +27.1% | +21.4% |
| Depreciation | 658 | 574 | 588 | 596 | 547 | 469 | 600 |
| Interest | 19.30 | 15.11 | 20.25 | 22.27 | 26.93 | 45.07 | 36.05 |
| Profit before tax | 4,636 | 6,469 | 5,310 | 3,375 | 3,880 | 3,208 | 2,964 |
| Tax | 1,121 | 1,311 | 1,233 | 862 | 922 | 739 | 646 |
| Net profit | 3,442 | 4,813 | 4,038 | 2,555 | 2,909 | 2,429 | 2,227 |
| Net profit margin | +17.2% | +24.1% | +23.1% | +17.0% | +18.9% | +21.5% | +17.6% |
| EPS (₹) | 43.52 | 63.86 | 50.50 | 31.14 | 36.66 | 30.61 | 28.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 162 | 162 | 161 | 161 | 161 | 161 | 161 |
| Reserves & surplus | 34,040 | 31,938 | 27,812 | 24,477 | 22,352 | 19,766 | 17,242 |
| Shareholders' funds (net worth) | 34,201 | 32,099 | 27,974 | 24,638 | 22,514 | 19,928 | 17,403 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 125 | 117 | 45.55 | 50.09 | 23.45 | 52.12 | 6.06 |
| Total debt | 125 | 117 | 45.55 | 50.09 | 23.45 | 52.12 | 6.06 |
| Total liabilities | 34,667 | 32,414 | 28,174 | 24,875 | 22,718 | 20,190 | 17,679 |
| Assets | |||||||
| Gross block | 10,500 | 8,670 | 8,046 | 7,766 | 7,388 | 7,066 | 6,698 |
| Net block | 5,194 | 3,878 | 3,719 | 3,809 | 3,910 | 4,066 | 4,151 |
| Capital work in progress | 978 | 638 | 670 | 504 | 268 | 355 | 320 |
| Investments | 17,616 | 17,351 | 13,794 | 11,909 | 10,974 | 9,726 | 7,190 |
| Inventories | 4,354 | 3,607 | 3,254 | 3,277 | 3,486 | 3,086 | 3,021 |
| Sundry debtors | 3,397 | 3,860 | 2,682 | 2,888 | 2,794 | 3,035 | 3,560 |
| Cash & bank balances | 519 | 278 | 333 | 966 | 1,428 | 875 | 523 |
| Loans & advances | 2,875 | 3,774 | 4,205 | 3,467 | 1,588 | 1,191 | 1,088 |
| Total current assets | 11,144 | 11,520 | 10,474 | 10,600 | 9,296 | 8,187 | 8,193 |
| Total current liabilities | 3,826 | 3,152 | 2,846 | 2,685 | 2,651 | 2,669 | 2,613 |
| Net working capital | 7,318 | 8,368 | 7,628 | 7,915 | 6,645 | 5,518 | 5,579 |
| Total assets | 34,667 | 32,414 | 28,174 | 24,875 | 22,718 | 20,190 | 17,679 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 82.74 | 165 | 29.48 | 177 | 295 | 262 | 64.47 |
| Net cash from operating activities | 2,832 | 3,301 | 3,727 | 3,035 | 2,773 | 3,460 | 2,018 |
| Net cash from investing activities | (1,344) | (2,309) | (2,883) | (2,758) | (2,464) | (3,361) | (1,127) |
| Net cash from financing activities | (1,322) | (1,074) | (709) | (425) | (427) | (65.80) | (694) |
| Net change in cash | 166 | (81.78) | 135 | (148) | (117) | 33.18 | 197 |
| Closing cash | 519 | 278 | 333 | 966 | 1,428 | 875 | 523 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +0.6% | +14.1% | +16.1% | -2.1% | +36.1% | -10.7% | - |
| EBITDA growth | -27.5% | +28.9% | +41.6% | -14.7% | +21.0% | +13.3% | - |
| PBT growth | -28.3% | +21.8% | +57.3% | -13.0% | +21.0% | +8.2% | +18.9% |
| Net income growth | -28.5% | +19.2% | +58.0% | -12.2% | +19.8% | +9.1% | - |
| Revenue CAGR (3Y) | +10.0% | +9.1% | +15.7% | +6.0% | +7.5% | -0.3% | +5.5% |
| EBITDA CAGR (3Y) | +9.8% | +15.9% | +13.5% | +5.4% | +14.1% | +13.1% | +19.3% |
| Profitability & leverage | |||||||
| Net income margin | +17.5% | +25.9% | +23.3% | +16.7% | +19.2% | +21.8% | +18.3% |
| Return on capital employed | +13.9% | +21.4% | +20.1% | +14.3% | +18.2% | +14.7% | +17.8% |
| Return on net worth | +10.6% | +17.2% | +15.5% | +10.7% | +13.9% | +13.0% | +14.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.55 | 0.29 | 0.52 | 0.87 | 0.85 | 1.73 | 1.71 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.09 | 2.39 | 2.21 | 1.99 | 2.13 | 1.64 | 1.97 |
| Inventory turnover | 5.04 | 5.82 | 5.35 | 4.45 | 4.68 | 3.70 | 4.30 |
| Debtors turnover | 5.53 | 6.10 | 6.28 | 5.30 | 5.28 | 3.43 | 3.76 |
| EPS (₹) | 43.52 | 63.86 | 50.50 | 31.14 | 36.66 | 30.61 | 28.75 |
| Dividend per share (₹) | 13.00 | 16.00 | 13.00 | 8.50 | 5.00 | 5.00 | 4.00 |
| Book value per share (₹) | 423.39 | 397.46 | 346.49 | 305.25 | 279.05 | 247.10 | 215.85 |
To see the full year-wise statements and ratios of Cipla Limited, buy the company report.
Board of directors of Cipla Limited
Cipla has 10 current directors and 30 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prathivadibhayankara Rajagopalan Ramesh Also directs: Nestle India Limited, Crompton Greaves Consumer Electricals Limited, Itc Hotels Limited and 5 more | Director | 01 Jul 2021 | 5 Years 3 Months | Current |
| Mandar Purushottam Vaidya | Director | 29 Jul 2022 | 4 Years 2 Months | Current |
| Yusuf Khwaja Hamied Also directs: Famid Sports Private Limited | Director | 21 Jul 1972 | 54 Years 3 Months | Current |
| Adil Zainulbhai Also directs: Network18 Media & Investments Limited, Reliance Retail Limited, Unnati Employment Network and 2 more | Director | 23 Jul 2014 | 12 Years 3 Months | Current |
| Kamil Hamied | Director | 01 Nov 2024 | 1 Years 11 Months | Current |
| Maya Hari | Director | 01 Nov 2024 | 1 Years 11 Months | Current |
Showing 6 of 10 current directors. View all directors
Peer comparison
Cipla Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹54,543 Cr (FY 2025) | 9.0% | Vadodara, Gujarat, India | |||
| Cipla Limitedthis company | ₹39,012 Cr (FY 2026) | ₹3,806.3 Cr | 9.8% | 5.3% | 25,952 | Mumbai, Maharashtra, India |
| Dr.Reddy's Laboratories Ltd | ₹33,741 Cr (FY 2025) | 17.0% | Hyderabad, Telangana, India | |||
| Aurobindo Pharma Ltd | ₹32,346 Cr (FY 2025) | 9.0% | Hyderabad, Telangana, India | |||
| Zydus Lifesciences Limited | ₹23,511 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Lupin Limited | ₹22,904 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Intas Pharmaceuticals Limited | ₹21,241 Cr (FY 2025) | 7.0% | Ahmedabad, Gujarat, India | |||
| Hetero Labs Limited | ₹16,537 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Biocon Limited | ₹16,470 Cr (FY 2025) | 5.0% | Bengaluru, Karnataka, India |
To see the full peer comparison of Cipla Limited, buy the company report.
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 29.20%, foreign institutional investors hold 20.20%, domestic institutional investors hold 34.60% and retail and other public shareholders hold 16.00%.
Sep 2026
QUARTER
29.20% Promoters
34.60% DII (Domestic Institutional)
20.20% FII (Foreign Institutional)
16.00% Retail & Others
Promoter holding - history
Now 29.20% · Sep 2026High 29.20% · Dec 2025Low 29.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 29.20% | 29.20% | 29.20% | 29.20% |
| Public | 70.80% | 70.80% | 70.80% | 70.80% |
Charges & borrowings
Open charges
None
Satisfied charges
₹68.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 17 Apr 1986 | 80066651 | The Hongkong and Shanghai Banking Corporation Limited (Lead Charge Holder) | ₹68.5 Cr | Satisfied |
To see the full charge records of Cipla Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Cipla Limited has 45 deals on record (41 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹675.99 Cr; the latest was in October 2025.
Total deals
45
Market trades
41
Acquisitions
2
Funding round
1
Secondary share transfer
1
Disclosed funding
₹675.99 Cr
Deals on record (5 of 45)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2024 | Market trade | ₹2,110.76 Cr | Buyer: GIC Singapore, Dsp Mutual Fund, Norges Bank On Account Of The Government Pension Fund Global Seller: 2 individuals |
| May 2024 | Secondary share transfer | Undisclosed | Seller: Okasa Pharma Private Limited , 3 individuals |
| May 2024 | Market trade | ₹2,750.58 Cr | Buyer: Icici Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, Dsp Mutual Fund Seller: Okasa Pharma Private Limited , 3 individuals |
| Mar 2019 | Market trade | ₹295.26 Cr | Buyer: MN Rajkumar Garments LLP Seller: an individual |
| Jun 2018 | Market trade | ₹304.47 Cr | Buyer: an individual Seller: Shree Riddhi Chemicals LLP , Hamsons Laboratories LLP |
To see the full deal history of Cipla Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cipla Limited has 996 court cases on record: 501 filed by Cipla, 495 filed against it. 182 cases are pending and 814 are disposed.
Total cases
996
Filed by the company
501
Filed against the company
495
Pending
182
Disposed
814
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 664 | 324 | 116 |
| District courts | 289 | 140 | 57 |
| Supreme Court | 36 | 24 | 3 |
| NCLAT | 7 | 7 | 6 |
Cases on record (5 of 996)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Pune, Maharashtra | Civil suit | Filed against the company by Eva Bio Trade X Pvt. Ltd. | Pending |
| High Court of Karnataka | Writ petition | Filed by the company against Karnataka State Medical Supplies Corporation Limited | Pending |
| District court, Chennai, Tamil Nadu | Criminal complaint | Filed against the company by Union of India, Represented by Drugs Inspector | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Court case (CRI M A) | Filed against the company by an individual | Pending |
| High Court for State of Telangana | Appeal | Filed against the company | Pending |
To see the full case history of Cipla Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Cipla Limited was last rated by Care on 27 Sep 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 27 Sep 2022 |
To see the full credit ratings and regulatory alerts of Cipla Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Cipla Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Cipla has 9 subsidiary companies and 7 associated companies. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.
9
Subsidiary companies
7
Associated companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Meditab Specialities Limited | U23240MH1996PLC104442 | |
| Cipla Health Limited | U24100MH2015PLC267880 | |
| Goldencross Pharma Limited | U24239MH2000PLC123766 | |
| Cipla Pharma and Life Sciences Limited | U24239MH2008PLC381559 | |
| Cipla Pharmaceutical S Limited | U24239MH2019PLC333266 | |
| Jay Precision Pharmaceutical S Private Limited | U33111MH2012PTC234037 |
To see the full group structure of Cipla Limited, buy the company report.
Employees & EPFO
Cipla Limited has a workforce of 25,952 employees on its EPFO records as of Oct 08, 2025, across 3 active EPFO establishments.
Employee count
25,952
Active EPFO establishments
3
Employee growth
4.75%
GST
Cipla has 38 GST registrations: 30 active and 8 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
38
Active
30
Cancelled / inactive
8
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACC1450B1ZE | Maharashtra | Active | 01 Jul 2017 |
| 27AAACC1450B2ZD | Maharashtra | Active | 21 Jul 2017 |
| 02AAACC1450B1ZQ | Himachal Pradesh | Active | 01 Jul 2017 |
| 03AAACC1450B2ZN | Punjab | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Cipla Limited, buy the company report.
Recent activity
Cipla Limited has 62 board changes on record since 1972: 38 appointments and 24 cessations. The latest: Achin Gupta was appointed as Managing Director on 01 Apr 2026.
Appointed
Achin Gupta was appointed as Managing Director.
Filing
Cipla Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Cipla Limited last Annual general meeting of members was held on 16 Jul 2025 as per latest MCA records.
Ceased
Punita Lal ceased to be Director.
Appointed
Kamil Hamied was appointed as Director.
Appointed
Maya Hari was appointed as Director.
Ceased
Mustafa Khwaja Hamied ceased to be Director.
Ceased
Samina Hamied ceased to be Director.
Appointed
Abhijit Jagdish Joshi was appointed as Director.
Ceased
Ashok Sinha ceased to be Director.
Appointed
Sharmila Nitin Paranjpe was appointed as Director.
Ceased
Radhakrishnan Sethuraman ceased to be Director.
56 earlier events are in the company report.
News
Maharashtra FDA Cancels Cipla Unit’s Drug Sale Licence Over Alleged Violations - Newspaper
From our blog
Frequently asked questions
Cipla is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 17 August 1935 (91+ years old) and is registered under CIN L24239MH1935PLC002380. Listed on BSE: 500087 and NSE: CIPLA.
Cipla reported revenue of ₹39,012 Cr for FY 2025-26 (up 5.3% YoY) based on consolidated financials.
Cipla has 10 current directors:
- Achin Gupta - Managing Director
- Prathivadibhayankara Rajagopalan Ramesh - Director
- Mandar Purushottam Vaidya - Director
- Yusuf Khwaja Hamied - Director
- Adil Zainulbhai - Director
- Kamil Hamied - Director
- Maya Hari - Director
- Abhijit Jagdish Joshi - Director
- Sharmila Nitin Paranjpe - Director
- Balram Bhargava - Director
The latest financial statements of Cipla on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 16 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Cipla is 27AAACC1450B1ZE, registered in Maharashtra. The company has 38 GST registrations in all, of which 30 are active and 8 are cancelled or inactive. Other active GSTINs include 27AAACC1450B2ZD (Maharashtra), 02AAACC1450B1ZQ (Himachal Pradesh), 03AAACC1450B2ZN (Punjab).
The CIN (Corporate Identification Number) of Cipla is L24239MH1935PLC002380. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Cipla is a listed company as per MCA records. Its shares are listed on both BSE (code: 500087) and NSE (symbol: CIPLA).
Cipla has 996 court cases on record: 501 filed by the company and 495 filed against it. 182 are pending. Most are in the high courts.
Cipla was incorporated on 17 August 1935, making it 91+ years old. It is registered with the Registrar of Companies, Mumbai.
Cipla has 45 deals on record (41 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹675.99 Cr; the latest was in October 2025.
The peers of Cipla by revenue are Sun Pharmaceutical Industries Limited, Dr.Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Zydus Lifesciences Limited, Lupin Limited and 3 more, all in the Pharma industry (API Manufacturers, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).